Keynote 224 Results In

Keynote 224 Results In. The results are consistent with those of. Pembrolizumab significantly improves overall survival (os) compared to placebo in advanced hepatocellular carcinoma (hcc) patients previously.

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: The results are consistent with those of.